Prof Etienne Brain discusses with ecancer the results of the MINDACT trial presented at EBCC-12.
He talks about the importance of this trial and why it was initiated in the first place and how the long term follow-up has proved successful in using certain drug combinations for chemotherapy against breast cancer.
He says age is also a factor that impacts the type and prognosis of chemotherapy used.